RNU6-816P
associated omics dataQ-omics provides the consensus-scored RNU6-816P profile across patient tissues and cancer cell-line models. RNU6-816P expression is associated with patient survival in 1 of 34 cancer types, with the highest sampling consensus in STAD.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNU6-816P — synthetic lethality, tumor antigen, and pembrolizumab response.
View premium →Survival associations
This table summarizes RNU6-816P survival associations across molecular data types. RNU6-816P RNA expression shows survival associations in the most cancer types (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNU6-816P RNA expression–survival associations across cancer types. High RNU6-816P expression shows unfavorable associations in STAD. The STAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify STAD as the clearest survival context for RNU6-816P RNA expression.
